{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T05:07:21Z","timestamp":1791176841728,"version":"4.1.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2007,10,9]],"date-time":"2007-10-09T00:00:00Z","timestamp":1191888000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2007,11]]},"DOI":"10.1038\/sj.bjc.6604023","type":"journal-article","created":{"date-parts":[[2007,10,9]],"date-time":"2007-10-09T13:49:32Z","timestamp":1191937772000},"page":"1322-1328","source":"Crossref","is-referenced-by-count":115,"title":["The value of including boys in an HPV vaccination programme: a cost-effectiveness analysis in a low-resource setting"],"prefix":"10.1038","volume":"97","author":[{"given":"J J","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B","family":"Andres-Beck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S J","family":"Goldie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2007,10,9]]},"reference":[{"key":"BF6604023_CR1","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.1016\/S0140-6736(07)60852-6","volume":"369","author":"KA Ault","year":"2007","unstructured":"Ault KA (2007) Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials. Lancet 369: 1861\u20131868","journal-title":"Lancet"},{"key":"BF6604023_CR2","doi-asserted-by":"publisher","first-page":"e138","DOI":"10.1371\/journal.pmed.0030138","volume":"3","author":"RV Barnabas","year":"2006","unstructured":"Barnabas RV, Laukkanen P, Koskela P, Kontula O, Lehtinen M, Garnett GP (2006) Epidemiology of HPV 16 and cervical cancer in Finland and the potential impact of vaccination: mathematical modelling analyses. PLoS Med 3: e138","journal-title":"PLoS Med"},{"key":"BF6604023_CR3","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1177\/0272989X02239651","volume":"23","author":"M Brisson","year":"2003","unstructured":"Brisson M, Edmunds WJ (2003) Economic evaluation of vaccination programs: the impact of herd-immunity. Med Decis Making 23: 76\u201382","journal-title":"Med Decis Making"},{"key":"BF6604023_CR4","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1093\/aje\/kwj077","volume":"163","author":"AN Burchell","year":"2006","unstructured":"Burchell AN, Richardson H, Mahmud SM, Trottier H, Tellier PP, Hanley J, Coutlee F, Franco EL (2006) Modeling the sexual transmissibility of human papillomavirus infection using stochastic computer simulation and empirical data from a cohort study of young women in Montreal, Canada. Am J Epidemiol 163: 534\u2013543","journal-title":"Am J Epidemiol"},{"issue":"Suppl 3","key":"BF6604023_CR5","doi-asserted-by":"publisher","first-page":"S26","DOI":"10.1016\/j.vaccine.2006.05.026","volume":"24","author":"G Clifford","year":"2006","unstructured":"Clifford G, Franceschi S, Diaz M, Munoz N, Villa LL (2006) Chapter 3: HPV type-distribution in women with and without cervical neoplastic diseases. Vaccine 24(Suppl 3): S26\u2013S34","journal-title":"Vaccine"},{"key":"BF6604023_CR6","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1016\/S0140-6736(05)67069-9","volume":"366","author":"GM Clifford","year":"2005","unstructured":"Clifford GM, Gallus S, Herrero R, Munoz N, Snijders PJ, Vaccarella S, Anh PT, Ferreccio C, Hieu NT, Matos E, Molano M, Rajkumar R, Ronco G, de Sanjose S, Shin HR, Sukvirach S, Thomas JO, Tunsakul S, Meijer CJ, Franceschi S (2005) Worldwide distribution of human papillomavirus types in cytologically normal women in the international agency for research on cancer HPV prevalence surveys: a pooled analysis. Lancet 366: 991\u2013998","journal-title":"Lancet"},{"key":"BF6604023_CR7","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/sj.bjc.6601024","volume":"89","author":"GM Clifford","year":"2003","unstructured":"Clifford GM, Smith JS, Aguado T, Franceschi S (2003a) Comparison of HPV type distribution in high-grade cervical lesions and cervical cancer: a meta-analysis. Br J Cancer 89: 101\u2013105","journal-title":"Br J Cancer"},{"key":"BF6604023_CR8","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1038\/sj.bjc.6600688","volume":"88","author":"GM Clifford","year":"2003","unstructured":"Clifford GM, Smith JS, Plummer M, Munoz N, Franceschi S (2003b) Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis. Br J Cancer 88: 63\u201373","journal-title":"Br J Cancer"},{"key":"BF6604023_CR9","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1093\/epirev\/mxj006","volume":"28","author":"EJ Dasbach","year":"2006","unstructured":"Dasbach EJ, Elbasha EH, Insinga RP (2006) Mathematical models for predicting the epidemiologic and economic impact of vaccination against human papillomavirus infection and disease. Epidemiol Rev 28: 88\u2013100","journal-title":"Epidemiol Rev"},{"key":"BF6604023_CR10","doi-asserted-by":"publisher","first-page":"3263","DOI":"10.1002\/(SICI)1097-0258(19991215)18:23<3263::AID-SIM315>3.0.CO;2-3","volume":"18","author":"WJ Edmunds","year":"1999","unstructured":"Edmunds WJ, Medley GF, Nokes DJ (1999) Evaluating the cost-effectiveness of vaccination programmes: a dynamic perspective. Stat Med 18: 3263\u20133282","journal-title":"Stat Med"},{"key":"BF6604023_CR11","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.mbs.2005.05.004","volume":"197","author":"EH Elbasha","year":"2005","unstructured":"Elbasha EH, Galvani AP (2005) Vaccination against multiple HPV types. Math Biosci 197: 88\u2013117","journal-title":"Math Biosci"},{"key":"BF6604023_CR12","doi-asserted-by":"publisher","first-page":"28","DOI":"10.3201\/eid1301.060438","volume":"13","author":"EH Elbasha","year":"2007","unstructured":"Elbasha EH, Dasbach EJ, Insinga RP (2007) Model for assessing human papillomavirus vaccination strategies. Emerg Infect Dis 13: 28\u201341","journal-title":"Emerg Infect Dis"},{"key":"BF6604023_CR13","volume-title":"Globocan 2002: Cancer Incidence, Mortality, and Prevalence Worldwide","author":"J Ferlay","year":"2004","unstructured":"Ferlay J, Bray F, Pisani P, Parkin DM (2004) Globocan 2002: Cancer Incidence, Mortality, and Prevalence Worldwide. Lyon: IARC Press"},{"key":"BF6604023_CR14","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1086\/315086","volume":"180","author":"EL Franco","year":"1999","unstructured":"Franco EL, Villa LL, Sobrinho JP, Prado JM, Rousseau MC, Desy M, Rohan TE (1999) Epidemiology of acquisition and clearance of cervical human papillomavirus infection in women from a high-risk area for cervical cancer. J Infect Dis 180: 1415\u20131423","journal-title":"J Infect Dis"},{"key":"BF6604023_CR15","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1038\/sj.bjc.6603575","volume":"96","author":"KM French","year":"2007","unstructured":"French KM, Barnabas RV, Lehtinen M, Kontula O, Pukkala E, Dillner J, Garnett GP (2007) Strategies for the introduction of human papillomavirus vaccination: modelling the optimum age- and sex-specific pattern of vaccination in Finland. Br J Cancer 96: 514\u2013518","journal-title":"Br J Cancer"},{"key":"BF6604023_CR16","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1056\/NEJMoa061741","volume":"356","author":"Future II Study Group","year":"2007","unstructured":"Future II Study Group (2007) Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 356: 1915\u20131927","journal-title":"N Engl J Med"},{"key":"BF6604023_CR17","doi-asserted-by":"publisher","first-page":"1928","DOI":"10.1056\/NEJMoa061760","volume":"356","author":"SM Garland","year":"2007","unstructured":"Garland SM, Hernandez-Avila M, Wheeler CM, Perez G, Harper DM, Leodolter S, Tang GW, Ferris DG, Steben M, Bryan J, Taddeo FJ, Railkar R, Esser MT, Sings HL, Nelson M, Boslego J, Sattler C, Barr E, Koutsky LA (2007) Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 356: 1928\u20131943","journal-title":"N Engl J Med"},{"issue":"Suppl 1","key":"BF6604023_CR18","doi-asserted-by":"publisher","first-page":"S97","DOI":"10.1086\/425271","volume":"191","author":"GP Garnett","year":"2005","unstructured":"Garnett GP (2005) Role of herd immunity in determining the effect of vaccines against sexually transmitted disease. J Infect Dis 191(Suppl 1): S97\u2013S106","journal-title":"J Infect Dis"},{"issue":"Suppl 3","key":"BF6604023_CR19","doi-asserted-by":"publisher","first-page":"S178","DOI":"10.1016\/j.vaccine.2006.05.116","volume":"24","author":"GP Garnett","year":"2006","unstructured":"Garnett GP, Kim JJ, French K, Goldie SJ (2006) Chapter 21: modelling the impact of HPV vaccines on cervical cancer and screening programmes. Vaccine 24(Suppl 3): S178\u2013S186","journal-title":"Vaccine"},{"key":"BF6604023_CR20","doi-asserted-by":"crossref","DOI":"10.1093\/oso\/9780195108248.001.0001","volume-title":"Cost-Effectiveness in Health and Medicine","author":"MR Gold","year":"1996","unstructured":"Gold MR, Siegel JE, Russel LB, Weinstein MC (1996) Cost-Effectiveness in Health and Medicine. New York: Oxford University Press"},{"key":"BF6604023_CR21","doi-asserted-by":"publisher","first-page":"6257","DOI":"10.1016\/j.vaccine.2007.05.058","volume":"25","author":"SJ Goldie","year":"2007","unstructured":"Goldie SJ, Kim JJ, Kobus KE, Goldhaber-Fiebert JD, Salomon JA, O'Shea MKH, Bosch FX, De Sanjose S, Franco EL (2007) Cost-effectivness of HPV 16,18 vaccination in Brazil. Vaccine 25: 6257\u20136270","journal-title":"Vaccine"},{"key":"BF6604023_CR22","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1016\/S0140-6736(06)68439-0","volume":"367","author":"DM Harper","year":"2006","unstructured":"Harper DM, Franco EL, Wheeler CM, Moscicki AB, Romanowski B, Roteli-Martins CM, Jenkins D, Schuind A, Costa Clemens SA, Dubin G (2006) Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 367: 1247\u20131255","journal-title":"Lancet"},{"key":"BF6604023_CR23","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1002\/(SICI)1097-0215(19981029)78:3<281::AID-IJC3>3.0.CO;2-R","volume":"78","author":"GY Ho","year":"1998","unstructured":"Ho GY, Kadish AS, Burk RD, Basu J, Palan PR, Mikhail M, Romney SL (1998) HPV 16 and cigarette smoking as risk factors for high-grade cervical intra-epithelial neoplasia. Int J Cancer 78: 281\u2013285","journal-title":"Int J Cancer"},{"key":"BF6604023_CR24","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1097\/00001648-200211000-00006","volume":"13","author":"JP Hughes","year":"2002","unstructured":"Hughes JP, Garnett GP, Koutsky L (2002) The theoretical population-level impact of a prophylactic human papilloma virus vaccine. Epidemiology 13: 631\u2013639","journal-title":"Epidemiology"},{"key":"BF6604023_CR25","unstructured":"International Agency for Research on Cancer (1976) Cancer Incidence in Five Continents, vol.3. Vol.3. IARC Scientific Publications No. 15 Lyon: IARC Press"},{"key":"BF6604023_CR26","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1093\/heapol\/13.3.249","volume":"13","author":"P Jha","year":"1998","unstructured":"Jha P, Bangoura O, Ranson K (1998) The cost-effectiveness of forty health interventions in Guinea. Health Policy Plan 13: 249\u2013262","journal-title":"Health Policy Plan"},{"key":"BF6604023_CR27","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1093\/aje\/kwm086","volume":"166","author":"JJ Kim","year":"2007","unstructured":"Kim JJ, Kuntz KM, Stout NK, Mahmud S, Villa LL, Franco EL, Goldie SJ (2007) Multiparameter calibration of a natural history model of cervical cancer. Am J Epidemiol 166: 137\u2013150","journal-title":"Am J Epidemiol"},{"key":"BF6604023_CR28","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1038\/sj.bjc.6600442","volume":"87","author":"M Molano","year":"2002","unstructured":"Molano M, Posso H, Weiderpass E, van den Brule AJ, Ronderos M, Franceschi S, Meijer CJ, Arslan A, Munoz N (2002) Prevalence and determinants of HPV infection among Colombian women with normal cytology. Br J Cancer 87: 324\u2013333","journal-title":"Br J Cancer"},{"key":"BF6604023_CR29","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.vaccine.2006.05.115","volume":"24S3","author":"N Munoz","year":"2006","unstructured":"Munoz N, Castellsague X, de Gonzalez AB, Gissmann L (2006) Chapter 1: HPV in the etiology of human cancer. Vaccine 24S3: S1\u2013S10","journal-title":"Vaccine"},{"key":"BF6604023_CR30","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/S1473-3099(07)70083-X","volume":"7","author":"AT Newall","year":"2007","unstructured":"Newall AT, Beutels P, Wood JG, Edmunds WJ, Macintyre CR (2007) Cost-effectiveness analyses of human papillomavirus vaccination. Lancet Infect Dis 7: 289\u2013296","journal-title":"Lancet Infect Dis"},{"key":"BF6604023_CR31","doi-asserted-by":"publisher","first-page":"2161","DOI":"10.1016\/S0140-6736(07)60946-5","volume":"369","author":"J Paavonen","year":"2007","unstructured":"Paavonen J, Jenkins D, Bosch FX, Naud P, Salmeron J, Wheeler CM, Chow SN, Apter DL, Kitchener HC, Castellsague X, de Carvalho NS, Skinner SR, Harper DM, Hedrick JA, Jaisamrarn U, Limson GA, Dionne M, Quint W, Spiessens B, Peeters P, Struyf F, Wieting SL, Lehtinen MO, Dubin G (2007) Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet 369: 2161\u20132170","journal-title":"Lancet"},{"issue":"Suppl 3","key":"BF6604023_CR32","doi-asserted-by":"publisher","first-page":"S11","DOI":"10.1016\/j.vaccine.2006.05.111","volume":"24","author":"DM Parkin","year":"2006","unstructured":"Parkin DM, Bray F (2006) Chapter 2: The burden of HPV-related cancers. Vaccine 24(Suppl 3): S11\u2013S25","journal-title":"Vaccine"},{"key":"BF6604023_CR33","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.3201\/eid1011.040222","volume":"10","author":"AV Taira","year":"2004","unstructured":"Taira AV, Neukermans CP, Sanders GD (2004) Evaluating human papillomavirus vaccination programs. Emerg Infect Dis 10: 1915\u20131923","journal-title":"Emerg Infect Dis"},{"key":"BF6604023_CR34","unstructured":"U.N. Population Division (2004) World Population Prospects: The 2004 Revision Population Database. http:\/\/esa.un.org\/unpp\/ Last accessed on January 19, 2007"},{"key":"BF6604023_CR35","unstructured":"U.S. Census Bureau (2000) Population Estimates Program, Population Division: Washington, DC. http:\/\/www.census.gov\/ipc\/www\/idb\/index.html: Last accessed on September 24, 2007"},{"key":"BF6604023_CR36","unstructured":"U.S. Central Intelligence Agency (2007) The World Factbook. https:\/\/www.cia.gov\/library\/publications\/the-world-factbook\/geos\/br.html: Last accessed on September 24, 2007"},{"key":"BF6604023_CR37","unstructured":"U.S.A.I.D. (2006) Demographic and Health Surveys. http:\/\/www.measuredhs.com\/ Last accessed on January 19, 2007"},{"key":"BF6604023_CR38","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1046\/j.1524-4733.2003.00234.x","volume":"6","author":"MC Weinstein","year":"2003","unstructured":"Weinstein MC, O'Brien B, Hornberger J, Jackson J, Johannesson M, McCabe C, Luce BR (2003) Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR task force on good research practices \u2013 modeling studies. Value Health 6: 9\u201317","journal-title":"Value Health"},{"key":"BF6604023_CR39","unstructured":"World Health Organization (2001) Investing in Health for Economic Development. Report of the Commission on Macroeconomics and Health. Geneva: World Health Organization"},{"key":"BF6604023_CR40","unstructured":"World Health Organization (2007) WHO CHOICE (Choosing Interventions That Are Cost-Effective). http:\/\/www.who.int\/choice\/en\/ Last accessed on January 19, 2007"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/6604023.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/6604023","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/6604023.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,18]],"date-time":"2024-02-18T11:43:41Z","timestamp":1708256621000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/6604023"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,10,9]]},"references-count":40,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2007,11]]}},"alternative-id":["BF6604023"],"URL":"https:\/\/doi.org\/10.1038\/sj.bjc.6604023","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,10,9]]}}}